Chapter 86
Antithrombotic Strategies in Endovascular Interventions
Current Status and Future Directions
Vishal Kapur,
Vishal Kapur
Search for more papers by this authorVishal Kapur,
Vishal Kapur
Search for more papers by this authorBook Editor(s):George D. Dangas MD, MACC, MSCAI, FAHA, FESC,
Carlo Di Mario MD, PhD, FRCP, FACC, FSCAI, FESC,
Holger Thiele MD,
Peter Barlis MBBS, MPH, PHD, FACC, FESC, FRACP,
Tayo Addo MD, Bimmer Claessen MD, Christian Hengstenberg MD, Nicholas Kipshidze MD,
George D. Dangas MD, MACC, MSCAI, FAHA, FESC
Professor of Medicine (Cardiology) & Surgery (Vascular) Professor of Cardiology Adjunct Professor of Internal Medicine
Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, USA
National Kapodistrian University of Athens, Greece
Medical University of Vienna, Austria
Search for more papers by this authorCarlo Di Mario MD, PhD, FRCP, FACC, FSCAI, FESC
Professor of Cardiology Director of the Structural Interventional Cardiology Division Honorary Consultant
University of Florence
University Hospital Careggi, Florence, Italy
Cardiologist Royal Brompton Hospital, London, UK
Search for more papers by this authorHolger Thiele MD
Professor of Cardiology at University of Leipzig
Heart Center Leipzig at University of Leipzig, Leipzig, Germany
Search for more papers by this authorPeter Barlis MBBS, MPH, PHD, FACC, FESC, FRACP
Professor of Cardiology Interventional Cardiologist
University of Melbourne, Melbourne, Victoria, Australia
St Vincent's & Northern Hospitals Victoria, Australia
Search for more papers by this authorFirst published: 06 May 2022
Summary
- PAD is highly prevalent disease with an estimated 200 million globally affected by it and carries a high risk for CAD, MACE and adverse events affecting the limbs, including acute limb ischemia and major amputation.
- Understanding the disease process and management is an ever evolving process.
- Multiple effective treatment modalities including medical management are available in the prevention and treatment of PAD.
Peripheral artery disease (PAD) affects the cerebral circulation and extracranial vessels, the aorta, great vessels, mesenteric and renal arteries, and the lower extremities. In recent years the number of endovascular procedures to treat this condition have significantly increased; however, despite this, little level 1 evidence is available regarding the role of antithrombotic therapy in patients undergoing these endovascular procedures. The current practice in this regard is heterogeneous and has been mainly driven by data from coronary artery disease and percutaneous coronary intervention (PCI). This chapter discusses the role of antithrombotic agents for endovascular intervention.
References
- Lassila R , Peltonen S , Lepantalo M , et al . Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin . Arterioscler Thromb 1993 ; 13 ( 12 ): 1738 – 1742 .
- Lee AJ , Fowkes FG , Rattray A , et al . Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease . Br J Haematol 1996 ; 92 ( 1 ): 226 – 230 .
- Lowe GD , Fowkes FG , Dawes J , et al . Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study . Circulation 1993 ; 87 ( 6 ): 1915 – 1920 .
- Smith FB , Lowe GD , Fowkes FG , et al . Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease . Atherosclerosis 1993 ; 102 ( 2 ): 155 – 162 .
- Aihara K , Azuma H , Akaike M , et al . Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors . J Atheroscler Thromb 2009 ; 16 ( 2 ): 127 – 134 .
- Hasenstab D , Lea H , Hart CE , et al . Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis . Circulation 2000 ; 101 ( 22 ): 2651 – 2657 .
- Hering J , Amann B , Angelkort B , Rottmann M . Thrombin–antithrombin complex and the prothrombin fragment in arterial and venous blood of patients with peripheral arterial disease . Vasa 2003 ; 32 ( 4 ): 193 – 197 .
- Patterson C , Stouffer GA , Madamanchi N , Runge MS . New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology . Circ Res 2001 ; 88 ( 10 ): 987 – 997 .
- Wilensky RL , Pyles JM , Fineberg N . Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase . Am Heart J 1999 ; 138 ( 2 Pt 1 ): 319 – 325 .
- Cvirn G , Hoerl G , Schlagenhauf A , et al . Stent implantation in the superficial femoral artery: short thrombelastometry-derived coagulation times identify patients with late in-stent restenosis . Thromb Res 2012 ; 130 ( 3 ): 485 – 490 .
- Takamori N , Azuma H , Kato M , et al . High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention . Circulation 2004 ; 109 ( 4 ): 481 – 486 .
- Meadows TA , Bhatt DL . Clinical aspects of platelet inhibitors and thrombus formation . Circ Res 2007 ; 100 ( 9 ): 1261 – 1275 .
- Ruggeri ZM . Platelets in atherothrombosis . Nat Med 2002 ; 8 ( 11 ): 1227 – 1234 .
- Offermanns S . Activation of platelet function through G protein-coupled receptors . Circ Res 2006 ; 99 ( 12 ): 1293 – 1304 .
- Weiss HJ , Aledort LM . Impaired platelet-connective-tissue reaction in man after aspirin ingestion . The Lancet 1967 ; 2 ( 7514 ): 495 – 497 .
- Berger JS , Krantz MJ , Kittelson JM , Hiatt WR . Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials . JAMA 2009 ; 301 ( 18 ): 1909 – 1919 .
- Hirsch AT , Haskal ZJ , Hertzer NR , et al . ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation . Circulation 2006 ; 113 ( 11 ): e463 – 654 .
- Weichert W , Meents H , Abt K , et al . Acetylsalicylic acid–reocclusion–prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease . Vasa 1994 ; 23 ( 1 ): 57 – 65 .
- Minar E , Ahmadi A , Koppensteiner R , et al . Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty . Circulation 1995 ; 91 ( 8 ): 2167 – 2173 .
- Ranke C , Creutzig A , Luska G , et al . Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease . Clin Investig 1994 ; 72 ( 9 ): 673 – 680 .
- Goldhaber SZ , Manson JE , Stampfer MJ , et al . Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study . The Lancet 1992 ; 340 ( 8812 ): 143 – 145 .
- Theroux P , Ouimet H , McCans J , et al . Aspirin, heparin, or both to treat acute unstable angina . N Engl J Med 1988 ; 319 ( 17 ): 1105 – 1111 .
- Becquemin JP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie . N Engl J Med 1997 ; 337 ( 24 ): 1726 – 1731 .
- Belch JJ , Dormandy J , Biasi GM , et al . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial . J Vasc Surg 2010 ; 52 ( 4 ): 825 – 833 .
- Thompson PD , Zimet R , Forbes WP , Zhang P . Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication . Am J Cardiol 2002 ; 90 ( 12 ): 1314 – 1319 .
- ISIS-2 . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . The Lancet 1988 ; 2 ( 8607 ): 349 – 360 .
- Baigent C , Collins R , Appleby P , et al . ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . BMJ 1998 ; 316 ( 7141 ): 1337 – 1343 .
- Roux S , Christeller S , Ludin E . Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis . J Am Coll Cardiol 1992 ; 19 ( 3 ): 671 – 677 .
- Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration . BMJ 1994 ; 308 ( 6921 ): 81 – 106 .
- CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) . The Lancet 1996 ; 348 ( 9038 ): 1329 – 1339 .
- Bhatt DL , Fox KA , Hacke W , et al . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events . N Engl J Med 2006 ; 354 ( 16 ): 1706 – 1717 .
- Allemang MT , Rajani RR , Nelson PR , et al . Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures . Ann Vasc Surg 2013 ; 27 ( 1 ): 62 – 67 .
- Robertson L , Ghouri MA , Kovacs F . Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment . Cochrane Database Syst Rev 2012 ; 8 : CD002071.
- Bonaca MP , Creager MA . Pharmacological treatment and current management of peripheral artery disease . Circ Res 2015 ; 116 ( 9 ): 1579 – 1598 .
- Schweizer J , Muller A , Forkmann L , et al . Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty . Angiology 2001 ; 52 ( 10 ): 659 – 669 .
- Koppensteiner R , Spring S , Amann-Vesti BR , et al . Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial . J Vasc Surg 2006 ; 44 ( 6 ): 1247 – 1253 .
- Ansel GM , Silver MJ , Botti CF Jr , et al . Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: a randomized trial . Catheter Cardiovasc Interv 2006 ; 67 ( 2 ): 288 – 297 .
- Baumgartner DA Jr . A time to say no . Ohio Med 1988 ; 84 ( 10 ): 783 – 784 .
- Dorffler-Melly J , Mahler F , Do DD , Triller J , Baumgartner I . Adjunctive abciximab improves patency and functional outcome in endovascular treatment of femoropopliteal occlusions: initial experience . Radiology 2005 ; 237 ( 3 ): 1103 – 1109 .
- Duda SH , Tepe G , Luz O , et al . Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone: a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis . Radiology 2001 ; 221 ( 3 ): 689 – 696 .
- Do DD , Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty . Radiology 1994 ; 193 ( 2 ): 567 – 571 .
- Pilger E , Lammer J , Bertuch H , et al . Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions: long-term results . Circulation 1991 ; 83 ( 1 ): 141 – 147 .
- Tan JY , Shi WH , He J , et al . [ A clinical trial of using antiplatelet therapy to prevent restenosis following peripheral artery angioplasty and stenting ]. Zhonghua Yi Xue Za Zhi 2008 ; 88 ( 12 ): 812 – 815 .
- Mahler F , Schneider E , Gallino A , Bollinger A . Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoro-popliteal PTA . Vasa 1987 ; 16 ( 4 ): 381 – 385 .
- Ge J , Han Y , Jiang H , et al . RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: longterm clinical and angiographic outcome . J Cardiovasc Pharmacol 2005 ; 46 ( 2 ): 162 – 166 .
- Kozuma K , Hara K , Yamasaki M , et al . Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz–Schatz coronary stent implantation . Am Heart J 2001 ; 141 ( 1 ): 124 – 130 .
- Park SW , Lee CW , Kim HS , et al . Effects of cilostazol on angiographic restenosis after coronary stent placement . Am J Cardiol 2000 ; 86 ( 5 ): 499 – 503 .
- Iida O , Nanto S , Uematsu M , et al . Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions . J Vasc Surg 2008 ; 48 ( 1 ): 144 – 149 .
- Ikushima I , Yonenaga K , Iwakiri H , et al . A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine . Med Devices (Auckl) 2011 ; 4 : 83 – 89 .
- Bittl JA , Chaitman BR , Feit F , et al . Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study . Am Heart J 2001 ; 142 ( 6 ): 952 – 959 .
- Stamler S , Katzen BT , Tsoukas AI , et al . Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair . J Vasc Interv Radiol 2009 ; 20 ( 1 ): 17 – 21 .
- Stabile E , Sorropago G , Tesorio T , et al . Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study . J Vasc Surg 2010 ; 52 ( 6 ): 1505 – 1510 .
- Eikelboom JW , Connolly S , Bosch J , et al . Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease . N Engl J Med 2017 ; 377 : 1319 – 1330
- Bonaca M , Bauersachs R , Anand S , et al . Rivaroxaban in Peripheral Artery Disease after Revascularization. VOYAGER PAD Trial . N Engl J Med 2020 ; 382 : 1994 – 2004
